FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome

FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome

The US Food and Drug Administration (FDA) has approved a supplemental indication for setmelanotide (Imcivree, Rhythm Pharmaceuticals) injection for chronic weight management in adults and pediatric patients age 6 and older with obesity due to Bardet-Biedl Syndrome (BBS). Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is the first FDA-approved therapy for BBS, a rare genetic disorder …

FDA Approves Setmelanotide for Obesity in Bardet-Biedl Syndrome Read More »